| Cat.No. | Name | Information |
|---|---|---|
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M9173 | Cilengitide TFA | Cilengitide TFA is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M13754 | OSU-T315 | OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
| M45159 | SGN-B6A | SGN-B6A is an integrin-targeted ADC that selectively targets solid tumors by recognizing ITGB6. |
| M45158 | Alintegimod | Alintegimod is an orally active variant activator of integrins αLβ2 and α4β1 that enhances T cell activation and adhesion. |
| M45157 | OS2966 | OS2966 is a first-in-class (first-in-class) neutralizing anti-CD29 monoclonal antibody that selectively modulates CD29 (integrin b1 subunit) and can be used in glioblastoma-related studies. |
| M45156 | JSM-6427 | JSM-6427 is an integrin α5β1 antagonist. |
| M45155 | MORF-057 | MORF-057 is an oral small molecule α4β7 integrin (integrin) inhibitor that can be used in studies related to ulcerative colitis (UC). |
| M45154 | PN-943 | PN-943 is a potentially first-in-class, orally active, specific α4β7 integrin antagonist peptide for studies related to inflammatory bowel disease (IBD). |
| M45153 | PLN-1474 | PLN-1474 is an orally active, selective ανβ1 integrin inhibitor with an IC50 value of <50 nM.PLN-1474 significantly reduces hepatic pSMAD3/SMAD3 levels, hepatic collagen gene expression, and hepatic OHP concentration in a mouse model of liver fibrosis. It can be used in studies related to liver cirrhosis and fibrosis. |
| M45152 | IDL-2965 | IDL-2965 is a small molecule heterocyclic compound that is also an inhibitor of αvβ1, αvβ3 , and αvβ6 for studies related to NAFLD and idiopathic pulmonary fibrosis. |
| M41632 | α7β1 integrin modulator-1 | α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. |
| M41631 | 3-Hydroxyxanthone | 3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one) is a xanthone compound, with . |
| M41630 | Orbofiban acetate | Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation. |
| M41629 | αvβ1 integrin-IN-2 | αvβ1 integrin-IN-2 is a potent inhibitor of integrins ανβ1 and α5β1 with IC50s of 0.9 nM, and 33 nM, respectively. |
| M41628 | Lotrafiban hydrochloride | Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease. |
| M41627 | REDV TFA | REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. |
| M41626 | Fradafiban hydrochloride | Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. |
| M31011 | Zalunfiban dihydrochloride | Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI). |
| M30942 | K34c | K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research. |
| M30902 | TC-I 15 | TC-I 15 (TC-I-15) is an allosteric, collagen-binding integrin α2β1 inhibitor with IC50 values of 26.8 μM and 0.4 μM for GFOGER and GLOGEN, respectively. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. |
| M30697 | EMD527040 | EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research. |
| M30656 | Valategrast hydrochloride | Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
